JP2011184466A5 - - Google Patents

Download PDF

Info

Publication number
JP2011184466A5
JP2011184466A5 JP2011143593A JP2011143593A JP2011184466A5 JP 2011184466 A5 JP2011184466 A5 JP 2011184466A5 JP 2011143593 A JP2011143593 A JP 2011143593A JP 2011143593 A JP2011143593 A JP 2011143593A JP 2011184466 A5 JP2011184466 A5 JP 2011184466A5
Authority
JP
Japan
Prior art keywords
composition
antagonist
monoclonal antibody
antibody
inhibits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011143593A
Other languages
English (en)
Japanese (ja)
Other versions
JP5462838B2 (ja
JP2011184466A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011184466A publication Critical patent/JP2011184466A/ja
Publication of JP2011184466A5 publication Critical patent/JP2011184466A5/ja
Application granted granted Critical
Publication of JP5462838B2 publication Critical patent/JP5462838B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011143593A 2005-09-01 2011-06-28 自己免疫性眼炎症性疾患を処置するためのil−23およびil−17のアンタゴニストの使用 Expired - Fee Related JP5462838B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71379205P 2005-09-01 2005-09-01
US60/713,792 2005-09-01
US83731206P 2006-08-11 2006-08-11
US60/837,312 2006-08-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008529228A Division JP2009507023A (ja) 2005-09-01 2006-08-30 自己免疫性眼炎症性疾患を処置するためのil−23およびil−17のアンタゴニストの使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013168006A Division JP2014005285A (ja) 2005-09-01 2013-08-13 自己免疫性眼炎症性疾患を処置するためのil−23およびil−17のアンタゴニストの使用

Publications (3)

Publication Number Publication Date
JP2011184466A JP2011184466A (ja) 2011-09-22
JP2011184466A5 true JP2011184466A5 (enExample) 2012-10-04
JP5462838B2 JP5462838B2 (ja) 2014-04-02

Family

ID=37686002

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008529228A Withdrawn JP2009507023A (ja) 2005-09-01 2006-08-30 自己免疫性眼炎症性疾患を処置するためのil−23およびil−17のアンタゴニストの使用
JP2011143593A Expired - Fee Related JP5462838B2 (ja) 2005-09-01 2011-06-28 自己免疫性眼炎症性疾患を処置するためのil−23およびil−17のアンタゴニストの使用
JP2013168006A Pending JP2014005285A (ja) 2005-09-01 2013-08-13 自己免疫性眼炎症性疾患を処置するためのil−23およびil−17のアンタゴニストの使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008529228A Withdrawn JP2009507023A (ja) 2005-09-01 2006-08-30 自己免疫性眼炎症性疾患を処置するためのil−23およびil−17のアンタゴニストの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013168006A Pending JP2014005285A (ja) 2005-09-01 2013-08-13 自己免疫性眼炎症性疾患を処置するためのil−23およびil−17のアンタゴニストの使用

Country Status (21)

Country Link
US (6) US20080199460A1 (enExample)
EP (3) EP2322219A3 (enExample)
JP (3) JP2009507023A (enExample)
CN (1) CN101296706B (enExample)
AT (1) ATE445415T1 (enExample)
AU (1) AU2006284841B2 (enExample)
BR (1) BRPI0615297A2 (enExample)
CA (1) CA2621086A1 (enExample)
CY (1) CY1110606T1 (enExample)
DE (1) DE602006009834D1 (enExample)
DK (1) DK1933869T3 (enExample)
ES (1) ES2333260T3 (enExample)
HR (1) HRP20100014T1 (enExample)
NO (1) NO20081574L (enExample)
NZ (2) NZ595262A (enExample)
PL (1) PL1933869T3 (enExample)
PT (1) PT1933869E (enExample)
RS (1) RS51142B (enExample)
SI (1) SI1933869T1 (enExample)
TW (2) TWI463993B (enExample)
WO (1) WO2007027761A2 (enExample)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
EP1954719A2 (en) 2005-12-02 2008-08-13 Genentech Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
EP2417974A1 (en) * 2007-02-28 2012-02-15 Schering Corporation Combination therapy for treatment of immune disorders
WO2008134659A2 (en) * 2007-04-27 2008-11-06 Zymogenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
JP5424330B2 (ja) * 2007-07-26 2014-02-26 国立大学法人大阪大学 インターロイキン6受容体阻害剤を有効成分とする眼炎症疾患治療剤
US20110212100A1 (en) * 2007-08-15 2011-09-01 Tracy Keller Methods for modulating development and expansion of il-17 expressing cells
CN101970490A (zh) 2007-11-27 2011-02-09 埃博灵克斯股份有限公司 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
CA2711696C (en) * 2008-01-09 2021-10-26 Reza Dana Therapeutic compositions for treatment of ocular inflammatory disorders
BRPI0907196B1 (pt) * 2008-02-21 2021-05-25 Kirin-Amgen Inc Uso de um antagonista de il-17ra-il-17rb
KR20170023209A (ko) 2008-05-05 2017-03-02 노비뮨 에스 에이 항-il-17a/il-17f 교차-반응성 항체 및 그의 사용 방법
US10117906B2 (en) * 2009-01-09 2018-11-06 The Schepens Eye Research Institute, Inc. Methods for reducing corneal nerves damage, corneal lymphangiogenesis or immunity to corneal antigens in dry-eye associated ocular surface diseases by IL-1Ra
US20120014970A1 (en) * 2009-01-09 2012-01-19 Reza Dana Therapeutic Compositions for Treatment of Corneal Disorders
AR075998A1 (es) * 2009-04-01 2011-05-11 Genentech Inc Tratamiento de trastornos resistentes a insulina.composicion farmaceutica. uso. kit
PE20120815A1 (es) 2009-05-05 2012-07-08 Novimmune Sa Anticuerpos anti il-17f y metodos de uso de los mismos
US9301997B2 (en) 2009-09-21 2016-04-05 Peptinov Sas Method of vaccination for limiting articular inflammation in rheumatoid arthritis and multiple sclerosis by administering IL-23 peptides
IN2012DN06720A (enExample) 2010-01-15 2015-10-23 Kirin Amgen Inc
US20110311527A1 (en) * 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
DK2598526T3 (en) 2010-07-29 2018-11-19 Eleven Biotherapeutics Inc CHEMICAL IL-1 RECEPTOR TYPE-I AGONISTS AND ANTAGONISTS
EP2625199B1 (en) * 2010-10-08 2017-11-22 Novartis AG Methods of treating psoriasis using il-17 antagonists
WO2012061448A1 (en) 2010-11-04 2012-05-10 Boehringer Ingelheim International Gmbh Anti-il-23 antibodies
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
EP2768946A1 (en) * 2011-10-21 2014-08-27 Baylor College Of Medicine Method to measure inflammation in the conjunctiva of patients with tear dysfunction
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
PE20142422A1 (es) 2012-04-05 2015-01-21 Hoffmann La Roche Anticuerpos biespecificos contra tweak humana e il 17 humana y usos de los mismos
US11078265B2 (en) 2012-05-03 2021-08-03 Boehringer Ingelheim International Gmbh Anti-IL-23 antibodies
CN104884473B (zh) 2012-05-22 2019-12-03 百时美施贵宝公司 Il-17a/f il-23双特异性抗体及其应用
WO2014093206A1 (en) * 2012-12-13 2014-06-19 Merck Sharp & Dohme Corp. Lyophilized spherical pellets of anti-il-23 antibodies
WO2014107737A2 (en) * 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Local delivery of il-17 inhibitors for treating ocular disease
CA2903706C (en) 2013-03-13 2024-01-23 Eleven Biotherapeutics, Inc. Chimeric cytokine formulations for ocular delivery
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US9603882B2 (en) 2013-08-13 2017-03-28 Industrial Technology Research Institute Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
WO2016014775A1 (en) 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of il-23a related diseases
WO2016036918A1 (en) 2014-09-03 2016-03-10 Boehringer Ingelheim International Gmbh Compound targeting il-23a and tnf-alpha and uses thereof
AR102417A1 (es) * 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
EP3193901B1 (en) 2014-12-23 2018-04-04 4D Pharma Research Limited Pirin polypeptide and immune modulation
ES2658310T3 (es) 2014-12-23 2018-03-09 4D Pharma Research Limited Una cepa de bacteroides thetaiotaomicron y su uso en la reducción de la inflamación
EP3928827A1 (en) 2014-12-31 2021-12-29 Stimwave Technologies Incorporated Antenna assembly
EP3250927B1 (en) * 2015-01-28 2020-02-19 H. Hoffnabb-La Roche Ag Gene expression markers and treatment of multiple sclerosis
BR112017014684A2 (en) 2015-02-04 2018-01-09 Boehringer Ingelheim International Gmbh methods of treatment of inflammatory diseases
CN104725514A (zh) * 2015-02-06 2015-06-24 中国药科大学 新型il23拮抗剂
PT3307288T (pt) 2015-06-15 2019-10-17 4D Pharma Res Ltd Composições compreendendo estirpes bacterianas
MA55434B1 (fr) 2015-06-15 2022-02-28 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
TWI759266B (zh) 2015-06-15 2022-04-01 英商4D製藥研究有限公司 包含細菌菌株之組合物之用途
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
CN108290058B (zh) 2015-09-17 2023-05-16 美国安进公司 使用il23途径生物标志物预测il23拮抗剂的临床应答
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MA45287A (fr) 2015-11-20 2018-08-22 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
PT3313423T (pt) 2016-03-04 2019-07-10 4D Pharma Plc Composições que compreendem a estirpe blautia bacteriana para tratar a hipersensibilidade visceral
TWI802545B (zh) 2016-07-13 2023-05-21 英商4D製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
RS61872B1 (sr) 2017-05-22 2021-06-30 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
WO2018215782A1 (en) 2017-05-24 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strain
RS63393B1 (sr) 2017-06-14 2022-08-31 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
EP3638271B1 (en) 2017-06-14 2020-10-14 4D Pharma Research Limited Compositions comprising bacterial strains
JP6840272B2 (ja) 2017-06-14 2021-03-10 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited 細菌株を含む組成物
WO2022032023A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il23r binding molecules and methods of use
US12077594B2 (en) 2020-08-05 2024-09-03 Synthekine, Inc. IL2RG binding molecules and methods of use
WO2022031890A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Ifngr2 binding molecules and methods of use
AU2021339381A1 (en) * 2020-08-05 2023-03-23 Synthekine, Inc. Compositions and methods related to receptor pairings
US12122839B2 (en) 2020-08-05 2024-10-22 Synthekine, Inc. IFNGR binding synthetic cytokines and methods of use
WO2022032006A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il2rb binding molecules and methods of use
CN116322754A (zh) 2020-08-05 2023-06-23 辛德凯因股份有限公司 Il10ra结合分子及使用方法
WO2022031929A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il12rb1-binding molecules and methods of use
US12291572B2 (en) 2020-08-05 2025-05-06 Synthekine, Inc. IL12 receptor synthetic cytokines and methods of use
WO2022031871A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Compositions and methods related to il27 receptor binding
MX2023001491A (es) 2020-08-05 2023-03-08 Synthekine Inc Moleculas de union a gp130 y metodos de uso.
WO2022032005A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il10rb binding molecules and methods of use
KR20250127176A (ko) 2020-08-05 2025-08-26 신테카인, 인크. IL27Rα 결합 분자 및 사용 방법
WO2022032022A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il10 receptor binding molecules and methods of use
JP2024536275A (ja) * 2021-10-03 2024-10-04 システィミューン, インク. がんを治療する方法及びその医薬組成物

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DE69427974T2 (de) 1993-04-29 2001-12-06 Unilever N.V., Rotterdam Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US6680057B1 (en) * 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor
DK0817847T4 (da) 1995-03-23 2009-10-05 Immunex Corp IL-17-receptor
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
ATE477273T1 (de) 1998-12-01 2010-08-15 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
ES2444710T3 (es) 2000-06-22 2014-02-26 Amgen, Inc. Uso de un anticuerpo específico para un polipéptido similar a IL-17
US8080247B2 (en) 2000-08-07 2011-12-20 Janssen Biotech, Inc. Anti-IL-12 antibodies
WO2002097048A2 (en) 2001-05-30 2002-12-05 Centocor, Inc. ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
US20050154046A1 (en) 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
AU2003226356A1 (en) 2002-04-12 2003-10-27 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
DK1576011T3 (da) * 2002-10-30 2009-11-30 Genentech Inc Inhibering af IL-17 produktion
US20040219150A1 (en) * 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
SI1601694T1 (sl) 2003-03-10 2010-01-29 Schering Corp Uporabe IL-23 antagonistov; sorodni reagenti
US7247711B2 (en) * 2003-05-09 2007-07-24 Centocor, Inc. IL-23p40 specific antibody
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
EP1641822B1 (en) 2003-07-08 2013-05-15 Genentech, Inc. Il-17 a/f heterologous polypeptides and therapeutic uses thereof
BRPI0510617A (pt) * 2004-05-03 2007-10-30 Schering Corp uso de expressão de il-17 para prever inflamação de pele; processos de tratamento
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
DE602005022871D1 (de) 2004-06-07 2010-09-23 Univ Ramot Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
WO2006007486A2 (en) * 2004-07-01 2006-01-19 New York University COMPOSITIONS AND METHODS FOR MODULATION OF RORϜt
DE102005032499B4 (de) * 2004-07-13 2009-10-22 Lg Electronics Inc. Dämpfer zur Vibrationsdämpfung und damit ausgerüstete Waschmaschine
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
JP2008520712A (ja) * 2004-11-19 2008-06-19 シンタ ファーマシューティカルズ コーポレーション ピリミジン化合物及びその使用
BRPI0518582A2 (pt) * 2004-11-24 2008-11-25 Therakine Corp implante para liberaÇço de medicamento intra-ocular
WO2006068987A2 (en) * 2004-12-20 2006-06-29 Schering Corporation Uses of il-23 antagonists in the treatment of diabetes mellitus
TW200641353A (en) 2005-02-14 2006-12-01 Wyeth Corp Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
PT1896073E (pt) * 2005-06-30 2013-05-28 Janssen Biotech Inc Composições, métodos e aplicações de anticorpos anti-il-23
UA96922C2 (en) 2005-06-30 2011-12-26 Эббот Леборейториз Il-12/p40 binding protein
EP2354160A1 (en) 2005-08-31 2011-08-10 Schering Corporation Engineered anti-IL-23-antibodies
AU2006330411B2 (en) 2005-12-29 2012-07-12 Janssen Biotech, Inc. Human anti-IL-23 antibodies, compositions, methods and uses
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds

Similar Documents

Publication Publication Date Title
JP2011184466A5 (enExample)
Wakefield et al. Scleritis: immunopathogenesis and molecular basis for therapy
JP2007535930A5 (enExample)
JP2015508063A5 (enExample)
JP2012021001A5 (enExample)
JP2009540018A5 (enExample)
JP2014205674A5 (enExample)
WO2008134659A3 (en) Antagonists to il-17a, il-17f, and il-23p19 and methods of use
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
UA109633C2 (uk) Антитіло людини проти тканинного фактора
TR201903026T4 (en) S100A4 ANTIBODIES AND THEIR THERAPEUTIC USES.
JP2016507470A5 (enExample)
EA201300530A1 (ru) Антитела к il-23
NZ590994A (en) Anti il-7r antibodies treatment of autoimmune and inflammatory disease
JP2017113019A5 (enExample)
JP2016509585A5 (enExample)
EA201290977A1 (ru) Гуманизированные антитела к il-25
JP2017501848A5 (enExample)
FI3687567T3 (fi) Adrenomedulliinin (adm) vasta-ainetta sitova aine käytettäväksi sairauden oireiden hoidossa tai ehkäisyssä
JP2008545145A5 (enExample)
EA201290172A1 (ru) Стабильные полипептиды, вариабельные домены антитела и антагонисты против tnfr1
JP2014507435A5 (enExample)
JP2016512817A5 (enExample)
JP2016534996A5 (enExample)
JO3188B1 (ar) بروتينات رابطة لمولد الضد محددة لمكون p لنظير النشا بالمصل